Researchers of a recent study evaluated the long-term health-related quality of life (HRQoL) and patient satisfaction with tapinarof cream 1% in the treatment of plaque psoriasis. The Dermatology Life Quality Index (DLQI) was assessed at each visit, and the Patient Satisfaction Questionnaire (PSQ) was administered at Week 40 or upon early termination.
By Week 40, 68.0% of patients achieved a DLQI score of 0 or 1, indicating that psoriasis had no impact on their HRQoL. Additionally, most patients strongly agreed or agreed with the PSQ questions related to confidence in tapinarof, satisfaction with its efficacy, application ease, cosmetic elegance, and preference of tapinarof over previous psoriasis therapies.
Reference: Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial [published online ahead of print, 2023 May 10]. J Am Acad Dermatol. 2023;S0190-9622(23)00771-5. doi:10.1016/j.jaad.2023.04.061
